Unicycive (UNCY) Director Laumas Sandeep Receives RSU Award

What Happened

• Laumas Sandeep, a director of Unicycive Therapeutics, was granted 47,941 restricted stock units (RSUs) on May 14, 2026. The award is reported as a derivative acquisition at $0.00 per share (an equity award/compensation, not a purchase).
• The grant has no immediate cash cost to the reporting person; value will depend on Unicycive's future stock price when/if the RSUs convert to shares.

Key Details

• Transaction date: 2026-05-14 (reported on an amended Form 4 filed 2026-07-28).
• Action/type: Award/Grant of RSUs (derivative), reported as "A".
• Shares granted: 47,941 RSUs; acquisition price: $0.00 (award).
• Vesting: 19,976 RSUs vested upon grant; the remaining 27,965 RSUs vest monthly at 3,995 shares over seven months beginning June 1, 2026, subject to continued service (per footnote).
• Shares owned after transaction: not stated in this filing.
• Filing status: This is an amended filing (filed after the original report date).

Context

• This is a compensation/retention award, not an open-market purchase or sale. Such grants are common for directors and are primarily a form of pay or retention rather than a direct signal of buying/selling intent.
• Because RSUs vest over time and convert to actual shares only upon vesting (and then may be subject to company rules or tax withholding), they do not immediately increase tradable float.